Kairos Pharma, LTD. Quarterly Net Income (Loss) Attributable to Parent in USD from Q3 2023 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Kairos Pharma, LTD. annual/quarterly Net Income (Loss) Attributable to Parent history and growth rate from Q3 2023 to Q3 2024.
  • Kairos Pharma, LTD. Net Income (Loss) Attributable to Parent for the quarter ending September 30, 2024 was -$1.05M, a 236% decline year-over-year.
  • Kairos Pharma, LTD. annual Net Income (Loss) Attributable to Parent for 2024 was -$2.6M, a 43.7% decline from 2023.
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$1.05M -$735K -236% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q3 2023 -$312K Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.